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1. Introduction 
Biotherapeutics drugs, such as antibodies, Fc-like fusion proteins, and therapeutic 
replacement enzymes, constitute the most rapidly growing drug class, and have become a 
major clinical success of human therapeutics over the past decade. These therapeutics of 
large-molecule have revolutionized the treatment of a variety of diseases in areas such as 
oncology, inflammatory and autoimmune diseases, hemophilia, cardiovascular disease,  
infectious diseases, and rare genetic diseases. In comparison with small-molecule 
therapeutics, biotherapeutics have a higher approval success rate and a similar development 
phase length. Physician and patients have accepted biotherapeutics drugs even though most 
of these products are administrated via injection. Many new biotherapeutics candidates are 
filling the pre-clinical and clinical pipelines of major Biopharmaceutical companies. The aim 
of this chapter is to provide a review on recent advances in Biotherapeutics drug discovery 
and development. Action mechanisms, tools for biotherapeutics generation, design 
processes, issues like safety and side effects, will be described. In addition, 
pharmacoeconomics and strategies to provide affordable biotherapeutics drugs will be 
discussed. 
2. An overview of biotherapeutics drug discovery and development 
Since the first recombinant-DNA-derived drug human insulin was approved for Eli Lilly by 
the UK and the US regulators in 1982, more than 170 biotherapeutics products have been 
launched to benefit quality of life of millions of patients worldwide. These biotherapeutics 
drugs compose of various types of biological molecular entities, and have revolutionized the 
treatment of a variety of human diseases ranging from cancer and autoimmune diseases to 
rare genetic disorders over the past three decades.  
Biotherapeutics drugs can be generally classified into three big groups (Table I), based on 
their physiological properties and mode of actions. The first group is peptides and small 
protein therapeutics which include growth factors, hormones, and cytokines. This category 
has been traditionally a major engine for the growth of biotherapeutics drugs, exemplified 
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by insulins, epoetin alpha (Epogen, Aranesp), and granulocyte colony-stimulating factor 
(Neupogen, Neulasta).  
 
-------------------------------------------------------------------------------------------------------------------------- 
                 Drug Classes                                                                 Examples 
--------------------------------------------------------------------------------------------------------------------------  
1)  Peptides and small therapeutic proteins 
A. Growth factors                                                                   erythropietins,   
                                                                                granulocyte colony-stimulating factors 
B. Hormones                                                                 insulin, human growth hormone, 
                                                                                         glucagon-like peptide analogs 
C. Cytokines                                                                          Interferon-, ,,  
                                                                                       Interleukins (Neumega, anakinra)   
 
2) Non-immune proteins  
A. Therapeutic replacement enzymes                            Naglazyme, Myozyme, Elaprase  
 
B. Blood factors                                                          Factor VIII; factor VIIa, factor IX 
 
C. Anticoagulants                                                           Tissue plasminogen activator, 
                                                                              recombinant hirudin, activated protein C  
 
3) Therapeutic antibodies and Fc-like fusion proteins 
A. Therapeutic antibodies                                            rituximab, adalimumab,  
                                                                                      cetuximab, trastuzumab 
B. Fc-Fusion proteins                                                          etanercept, CD2-Fc,  
                                                                                          abatacept, Nplate 
-------------------------------------------------------------------------------------------------------------------------- 
Table 1. Drug classes of Biotherapeutics drugs 
The second group is non-immune therapeutic proteins which include therapeutic 
replacement enzymes, blood factors, and anticoagulants. This category typically includes 
recombinant proteins used for treatment of rare genetic disorders, i.e. Naglazyme for 
Maroteaux-Lamy syndrome, Myozyme for Prompe disease, and Elaprase for Hunter 
syndrome. Though relatively small, this is a rapidly growing sector of Biotherapeutics 
drugs. 
The third group is therapeutic antibodies and Fc-like fusion proteins. This category ranks 
the most rapidly growing group of biotherapeutics drugs, propelled by the success of the 
“big 6”: Enbrel, Remicade, and Humira for autoimmune diseases; Rituxan, Herceptin, and 
Avastin for treatment of several types of cancers. By 2010, at least 11 products from this 
group have reached global sales of exceeding 1 billion US dollars.  
Over the past 10 years, biotherapeutics drugs have become the fastest growing class of 
therapeutic agents. The total sales of biotherapeutic drug in the US alone reached close to 
$50 billion in 2010 (Aggarwal 2010). Novel biotherapeutics molecules, i.e. monoclonal 
antibodies and fusion proteins especially, have been entering clinical study at a rate of over 
40 per year since 2007 (Reichert 2011). Hundreds of antibodies and fusion proteins are 
undergoing clinical evaluation. By the end of 2010, over 30 of this kind of drug candidates 
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were in Phase2/3 or Phase 3 clinical studies, representing a substantial proportion of the late 
stage therapeutics pipeline. In addition, biotherapeutics drugs have a significantly higher 
likelihood of being a first-in-class therapy compared with small molecule drugs, considering 
their novelty and quality. The pharmaceutical and biotechnology industry has therefore 
been investing increasingly substantial resources in the discovery and development of 
biotherapeutics products.  
Clearly, the process of the discovery and development of a biotherapeutics drug poses 
challenges that are different from those set by a traditional small molecule drug. In general, 
biotherapeutics drugs are designer drugs whose mode of action in an underlying disease 
pathophysiology is usually better understood than those targeted by small-molecule drugs. 
The data derived from relevant models can support a more rational clinical development 
program, facilitating better predictions of dosing, efficacy and safety profiles in comparison 
with small molecule therapeutics. Biotherapeutics drugs therefore have a higher approval 
success rate, though a similar development phase length,  compared with those of small 
molecule drugs (Reichert 2010). However, as proteins or peptides produced from living 
cells, biotherapeutics agents require more complicated manufacturing and characterization 
process to minimize product variation among bath-to-batch. They must be well 
characterized with regards to potency, identity, quality, purity, and stability.  
Advancements in biotherapeutics engineering technologies, and a deeper understanding of 
mechanism for biotherapeutics action, their safety and side effects in human, have been in 
action in producing a new generation of biotherapeutics drugs. Experience gained through 
current biotherapeutics has helped guide future development process via strength building, 
limitation overcoming, and opportunity seizing. Details of these scientific and technologic 
knowledges are reviewed in the following sections. By examining the cost issue associated 
with biotherapeutics drugs, insights into the strategies for affordable biotherapeutics drugs 
are also discussed. 
3. Mechanisms for biotherapeutics action  
Diverse mechanisms have been employed by biotherapeutics drugs to achieve therapeutic 
efficacy and disease modulation. These include direct enzyme replacement, stimulation of 
biological signal responses, enzymes inhibition, effector functions, Toxin conjugation, 
cytokine and growth factor blockade. 
A. Direct enzyme replacement 
Insulin for diabetes control  is considered to be the oldest example for enzyme replacement 
therapy since its breakthrough discovery more than 80 years ago (Hirsch 2005). The 
development of recombinant insulin in early 1980 eliminates side effects posted by bovine 
and porcine extracted products. Since then, new generations of insulin analogues such as 
rapidly-acting analogues and long-acting analogues have been produced. A more recent 
example for enzyme replacement drugs is the treatment of rare disease disorders such as 
Lysosomal storage disorders. Gaucher disease and Prompe disease are caused by the lack or 
dysfunction of an enzyme in the lysosome. Imiglucerase (Genzyme), a recombinant version 
of glucocerebrosidase, can rescue the deficiency of the disease when this replacement drug 
is injected regularly throughout patients’ lives. After the medical and commercial success in 
Gaucher disease, a number of enzyme replacement therapies have been approved for 
several different diseases. Agalsidase  (Genzyme) and agalsidase  (Shire) are for Farbry 
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disease; Laronidase (BioMarin/Genzyme) for Hurler-Schcic syndrome; Idursulphase (Shire) 
for Hunters Syndrome; Alglucosidase  (Genzyme) for Pompe disease; galsuphase 
(BioMarin) for Maroteaux-Lamy syndrome. All these products are in orphan diseases group. 
Recombinant Factor VIII, VIIa, and IX play an important role in blood clotting and are used 
for people who are genetically deficient (Hemophilia A & B) or have undergone blood loss 
during a surgery or trauma. 
B. Effector functions 
The Fc portion of an antibody, composed of the hinge and constant domains, can 
communicates with the immune system once the antibody binds its target. The 
communication is through effector functions which include antibody-dependent cellular 
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-
dependent cytotoxicity (CDC). ADCC and ADCP are through the interaction between Fc 
and FcR receptors expressed on a variety of immune cells such as natural killer cells, 
monocytes, neutrophils and macrophages. CDC is mediated via the interaction of Fc with 
complement proteins such as C1q. Several antibody therapeutics, including rituximab, 
adalimumab, cetuximab, trastuzumab and alemtuzumab support ADCC and CDC in vitro, 
which might also contribute to the therapeutic efficacy in clinical setting such as the 
destruction of tumor cells or viral infected cells. 
C. Cytokine and growth factor blockage. 
Tumor necrosis factor (TNF) antagonists, such as therapeutic antibody infliximab, 
adalimumab, golimumab, certolizumab, and Fc fusion protein etanercept, are presently the 
most successful class of biotherapeutics drugs for inflammatory diseases. One major mode 
of action for these antagonists are blocking either soluble TNF or membrane associated 
factor. Other biotherapeutics drugs with a similar mechanism include canakinumab (Anti-
IL-1┚ antibody) for the treatment of cryopyrin-associated periodic syndrome and 
ustekinumab (anti-IL-12/IL-23 antibody) for the treatment of psoriasis. 
D. Receptor blockage and modulation 
Therapeutics antibody can target receptors to block ligand-receptor interaction, which also 
down-regulate surface expression of the targeted receptor. These antibodies include 
tocillizumab (targeting IL-6 receptor), efalizumab (targeting ┙L integrin [CD11a/LFA1]), 
and natalizumab (targeting ┙4 subunit of ┙4┚1 & ┙4┚7 integrin). However, targeting surface 
receptors can potentially result in antigen-induced clearance of therapeutic antibody and 
decrease its serum half-life. This mechanism can also theoretically have a greater risk for 
triggering immunogenic response, as antigen-dependent internalization can increase MHC 
class II antigen processing.  
E. Toxin conjugation 
To enhance monoclonal antibody utility in the clinical treatment of cancer, cytotoxic drugs 
such as doxorubicin, calicheamicin, auristatins, and maytansinoids, have been conjugated 
with monoclonal antibodies (Senter 2009). Targeted site-specific and intracellular delivery of 
toxins into tumor cells elicits potent antitumor activity in both preclinical and clinical 
studies. Currently there are one approved antibody conjugated molecule (Gemtuzumab 
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F. Stimulation of biological signal responses 
Romiplotim, a peptide –Fc fusion protein of thrombopoietin analogue, activates Tie2 
receptor for the platelet regeneration to treat chronic idiopathic thrombocytopenic purpura. 
Exenatide mimics a natural peptide (Glucagon-like peptide 1) but is resistant to degradation 
by protease DPP4 for diabetes control. Erythropietins trigger red blood cell regeneration for 
anemia. Granulocyte colony-stimulating factors set off white blood cells regeneration for 
neutropenia; Neumega (recombinant IL-11 receptor agonist) stimulates biological signaling 
response for chemotherapy-induced thrombocytopenia.  
G. Enzymes inhibition 
Ecallantide (Dyax), a Kunitz domain-based scaffold, targets human plasma kallikrein for the 
treatment of attacks of hereditary angioedema. Recombinant hirudin is an inhibitor of 
thrombin, and activated protein C also has anti-thrombic activity.  
4. Tools for biotherapeutics generation  
The success of biotherapeutics drugs is attributed to the great technology and tool 
development for biotherapeutics generation over the past three decades. Various selection 
technologies,  multiple protein engineering platforms, a profusion of biotherapeutics 
formats and scaffolds, new production systems, and new methods for increasing stability 
and aggregation resistance, have blossomed into a next wave of therapeutic candidates. The 
following is a summary of early tools and recent developments. 
A. Hybridomas 
Mouse hybridomas generated from the stable fusion of immortalized myeloma cells with B 
cell from immunized mice is the first developed and most widely used technology for the 
generation of monoclonal antibodies (Kohler and Milstein 1975). This technology has a 
ubiquitous use and a broad success in drug discovery research. However due to mouse 
antibodies’ high immunogenicity in humans, the weak interaction with human complement 
and FcRs, and short half-life with no binding to human salvage receptor FcRn, they have a 
very low clinical success rate. These limitations have been largely overcome by 
chimerization and humanization in the current era of antibody therapeutics.  
B. Chimerization and humanization 
Chimerization of an antibody is joining the variable domains of a mouse monoclonal 
antibody to the constant domains of a human antibody (Boulianne et al. 1984; Morrison et al. 
1984). This tool utilizes a detailed understanding of the structure and function of 
immunoglobulin domains as well as the determinants of antigen binding. The humanization 
strategies involve transferring the complementary-determining regions (CDRs, the antigen-
binding loops) from a mouse antibody to a human IgGs, and additional mutagenesis of one 
or more framework-region residues back to the parent mouse antibody.  
C. Human antibodies from transgenic mice 
A growing number of antibodies entering clinical trials and the market are completely 
human. Some of them are derived from transgenic mice that express human 
immunoglobulin genes (Lonberg 2005). Mice that are transgenic for human immunoglobulin 
genes and have disrupted mouse immunoglobulin heavy-chain and Ig light-chain can be 
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immunized with target-antigens to produce human antibodies. B cells that express specific 
human antibodies can be cloned for hybridomas, similar to the generation of mouse 
monoclonal antibodies. The binding affinity of these transgenic-mouse-generated antibodies 
is often high, likely due to the in vivo affinity maturation process and therefore obviating 
the in vitro affinity optimization steps. Human IgG1 output from transgenic mice and the 
direct use of hybridomas cell lines for human antibody production can allow early screening 
for biological function and for pre-clinical development. One challenge to use transgenic 
mice is to derive antibodies that are crossreactive with mouse antigens. It is often desirable 
to evaluate biological function of the species-crossreactive antibodies in animal models of 
disease. In transgenic mice, self-reactive antibody-producing cells are selected against by the 
processes of immune tolerance induction.  
D. Human antibodies from phage-display libraries 
Phages encoding a single-chain V-domain antibody fragment(scFv) on their surface and 
selective recovery of phage on the basis of antigen binding were first reported by 
McCafferty et al (McCafferty et al. 1990). Diverse human immunoglobulin-heavy-chain V 
(VH) gene segments and light-chain V (VL) gene segments were prepared from peripheral-
blood lymphocytes of non-immunized donors by PCR, and scFvs genes were made by 
randomly combining VH and VL gene segments using PCR. The combinatorial library (up 
to ~1011 genes) can be cloned for display on the surface of phage and used to identify scFvs 
that bind target antigens. Further progress in phage-display technology has included 
display of Fabs and high-throughput screening methods adapted from small-molecule drug 
discovery. A particular strength of phage-display libraries, in contrast to hybridomas 
technology, is the direct selection for specific binding properties, such as species 
crossreactivities. In addition, phage-display technology has a capability to provide very 
large collections of antibodies, which allows the identification of high potency antibodies or 
with rare combinations of properties. 
E. Glycoengineering 
Glycoengineering is changing protein-associated carbohydrate to alter pharmacokinetic 
property or biological function of therapeutic proteins, because of the ability to manipulate 
DNA sequences. Glycoengineering can increase molecular stability, solubility, serum half-
life, in vivo biological activity, and reduce immunogenicity. One well known example of 
this technology is the discovery of darbepoetin alfa, a hyperglycosylated analogue of 
erythropoietin that contains two additional N-linked carbohydrates (Elliott et al. 2003). The 
introduction of new N-linked glycosylation consensus sequences into desirable position in 
the peptide backbone can increase sialic acid containing carbohydrate, thereby increasing 
serum half-life. Another aspect of glycoengineering is generating various glycoforms of a 
glycoprotein. An engineered CHO cells with overexpressing galactosyltransferease and 
sialyltransferase can maximize sialic acid content of recombinant glycoproteins produced 
(Weikert et al. 1999). A fucosyl-transferase knock-out cell line produce antibody protein 
with fucose-free glycan attached at Asn 297 in the IgG-Fc region, which possess a 
significantly increased ADCC activity (Niwa et al. 2004; Shields et al. 2002). Another 
glycoengineering approach involves in vitro treatment of a purified glycoprotein with 
glycosidases or glycotransferases. Cerezyme, the recombinant glucocerebrosidase, has been 
treated with neuraminidase, -galactosidase and -hexosaminidase, to trim outer 
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oligosaccharide to expose core mannose residues underneath for macrophage targeting 
(Brady and Barton 1994; Hoppe 2000). 
F. Multispecific antibodies 
Bispecific antibodies that are capable of strong and specific binding with two different 
antigens have been on the scene for decades. They can target two or more disease 
mechanisms as a single agent and provide a unique alternative to combination therapies. 
More importantly, bispecific antibodies can achieve some therapeutic strategies that are not 
feasible with conventional monospecific monoclonal antibody combination. For instance, by 
targeting both immune effector cells surface molecules and tumor cell surface markers, 
bispecific antibodies could preferentially recruit activating effector cells to kill tumor cells 
(Chames and Baty 2009). Bispecific antibodies have been used for the site-specific targeting 
insulin and transferring receptors on the blood-brain barrier (BBB) as transporter and anti-
amyloid- targeting binding across BBB is significantly increased (Boado et al. 2010). 
Bispecific antibodies can be generated via several approaches, including cell fusion-based 
quadromas and triomas(Nisonoff and Rivers 1961), chemical cross-linking-based approach 
(Graziano and Guptill 2004), and recombinant technology-based approaches, such as using 
Ig hetero-oligomerization domain(Muller et al. 1998; Ridgway et al. 1996),  non-Ig hetero-
oligomerization domains, scFv-based bispecific, and single variable domain-based bispecific 
(Holt et al. 2003), dual-variable domain immunoglobulin(Wu et al. 2007). 
G. Intrabodies 
Intrabodies are antibodies that are designed to be expressed intracellularly against different 
target antigens present in cytosol, nucleus, endoplasmic reticulum, mitochondria, 
peroxisomes, and plasma membrane (Lo 2008; Williams and Zhu 2006). Though Introbodies 
have the potential of interfering with intracellular biosynthetic pathways, the major obstacle 
of Intrabodies is the absence of efficient in vivo delivery method to live target cells(Stocks 
2006). Current attempts are using recombinant adenovirus and vaccinia virus vetors or 
immunoliposomes (Williams and Zhu 2006). 
H. Protein engineering,  
Molecular biology techniques such as site-directed mutagenesis and error-prone PCR have 
been routinely used for biotherapeutics generation. Computational modeling and structure-
based drug design with three-dimentional structural information are widely applied to 
protein engineering. Screening technologies such Peptide Phage-display Libraries, “Peptides 
on Plasmids” libraries, Ribosome display, mRNA display, CIS display, and DNA display, 
have also been utilized for biotherapeutics lead generation (McGregor 2008).  
5. Design processes for biotherapeutics  
Biotherapeutics-based drug development is driven by unmet medical needs. Designing a 
successful biotherapeutics requires understanding of several critical areas.  
First is the understanding of disease biology. Human diseases are complex and 
heterogeneous that multiple redundant and distinct mechanisms determine the final disease 
outcome and contribute to multifaceted, distinct disease symptoms (acute versus chronicle) 
and pathologies. It is important to evaluate if there are good preclinical models and 
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understand the limitation of the predictive power of these animal models. Translational 
medicine helps define good biomarkers for disease progress and designing clinical trials 
with appropriate end points that reflect the role of the specific targeted mechanism in a 
complex disease. 
Second is the understanding of target biology. It is critical to determine which target should 
be chosen in a defined mechanism. Targeting either soluble ligands or surface receptors, 
serving as agonist or antagonist, need to be determined. An overall target biology within the 
context of the disease (specific aspects of the disease that are driven by the target) need to be 
understood. Typically drug targets can be classified into three groups. The first group is so-
called “clinically validated targets” because of their proof-of-activity shown in humans. This 
validated approach has a high probability of success, but the competition is crowded and 
freedom to operation is decreased. The second group is experimentally- validated targets, 
whose importance for disease mechanisms have been demonstrated by a vast literature. 
Most cytokines and associated receptors for immunological disorders and tyrosine kinases 
receptors in oncology fall into this category, as the mechanisms driving these disorders are 
reasonably well known. The third group of targets is those new or less well studied target 
proteins that might be involved in pathogenic disorders. More extensive and careful 
validation is required. They are with a greater potential for new therapeutic breakthroughs, 
but carrying out a greater risk of development failures.  
Lastly is the advancement of biotherapeutic technologies. We need to understand affinity 
and potency, specificity and cross-reactivity, physicochemical properties, immunogenicity, 
expression and purification, solubility and stability, pharmacokinetics and 
pharmacodynamics, and formulability and manufacturability. In short, we need to know 
what features a good biotherapeutic protein must possess by incorporation of lessons 
learned over the years, as well as identify key issues critical for technology advancement. 
6. Safety and side effects of biotherapeutics  
Administration of biotherapeutics carries the risk of immune response and numerous 
adverse effects that are related to their specific targets and organ-specific adverse events 
(Giezen et al. 2008; Hansel et al. 2010). The following discuss a range of adverse effects 
encountered with biotherapeutics, some of which have been fatal, and strategies to 
minimize these events. These events include those documented for licensed biotherapeutics 
as well as examples of side effects found during exploratory clinical studies. Some of the 
severe adverse effects are not anticipated from currently available preclinical screening tools 
and animal models. These lessons can provide new strategies and guidelines needed for the 
development of safer and more efficacious biotherapeutics. 
A. Acute Immune reactions 
Biotherapeutics can induce acute infusion reactions either due to their mechanism of action 
and/or their foreign nature of the molecule and/or co-purified impurities that result in 
acute reactions either via innate immunity or due to the reaction with pre-existing, or 
induced IgE antibodies. Clinical magnification can range from local skin reactions at the 
injection site through acute anaphylaxis and systemic inflammatory response syndrome. For 
rituximab (Coiffier et al, 2002), first dose infusion reactions combine serum sickness, tumor 
lysis syndrome and cytokine release syndrome, primarily as a result of its mechanism of 
action. These initial reactions can be minimized by appropriate hydration and 
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premedication, and cautious incremental increases in the rate of infusion. Acute 
anaphylactic and anaphylactoid reactions are commonly described for cetuximab which has 
been attributed to pre-existing IgE antibodies against galactose-┙1,3-galactose which is 
expressed on the cetuximab molecule (Chung et al. 2008).  
B. Immunogenicity 
The development of immunogenicity, or anti-drug antibodies, has important clinical 
ramifications. The development of immunogenicity could lead to a number of important 
clinical implications, including alternation in PK and loss of efficacy through neutralization, 
an increase in adverse events associated with drug-antibody interactions, and, dependent 
upon the nature of the biotherapeutic, the potential for cross reactivity of antibodies with 
endogenous ligands. As such, the assessment of immunogenicity and the assessment of 
ADA’s clinical implications is a crucial part of biotherapeutics development. The 
development and appropriate validation of anti-drug antibody assays is a fundamental 
necessity in understanding ADA. Interference by a parent drug and existing antibodies 
must be evaluated. In addition, a comprehensive assessment of the clinical implications of 
the ADA must be assessed in the clinical setting to evaluate both safety and efficacy, as well 
as any reasonable cross-reactive effect. 
C. Infections 
A well documented side effect of biotherapeutics is infection, which is generally due to 
removal of the therapeutic targets that have a protective function in the normal immune 
system. An increased risk of tuberculosis infection has been associated with TNF┙-specific 
biotherapeutics (Schneeweiss et al. 2007). Progressive multifocal leukoencephalopathy 
(PML) is a rapidly progressive demyelinating disease that is due to reactivation of the 
infection in the central nervous system with the polyoma virus John Cunningham virus 
(JCV), though most healthy people are seropositive for JCV. The risk of PML is about 1 in 
1,000 multiple sclerosis patients treated with natalizamab (Yousry et al. 2006). A number of 
PML cases are found for rituximab (Carson et al. 2009) and efaliziumab (Molloy and 
Calabrese 2009).  
D. Autoimmune diseases 
Biotherapeutics such as monoclonal antibodies have the capacity through their 
immunomodulatory actions to cause various autoimmune conditions (Mongey and Hess 
2008), such as Lupus-like syndromes and drug-related lupus, Thyroid disease, and 
autoimmune colitis. For instance, the treatment of TNF┙ specific monoclonal antibodies has 
been found associated with the development of anti-nuclear antibodies and anti-bodies to 
double-stranded DNA as well as with lupus-like syndromes (Mongey and Hess 2008). When 
used in multiple sclerosis, anti-CD52 immunosuppressive monoclonal antibody 
alemtuzumab was found to cause antibody-mediated thyroid autoimmunity in almost 25% 
of study patients (Coles et al. 1999). 
Other agents have observed autoimmune events as a result of their direct mechanism of 
action. Anti-Cytotoxic T-lymphocyte-antigen 4 (CTLA4) specific monoclonal antibodies such 
as ipilimumab and tremelimumab increase T-cell stimulation and has been shown antitumor 
activity (Maker et al. 2005), but also cause an autoimmune enterocolitis and other immune-
related adverse events such as rash and hepatitis (Peggs et al. 2006).  
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Some antibody therapeutics such as infliximab and ustekinumab (Rennard et al. 2007; Weiss 
et al. 2007) have even been found inducing tumorigenicity in auto-immune patients. 
F. Platelet and thrombotic disorders 
Drug-induced immune thrombocytopaenia  is a decrease in the number of circulatory 
platelets in the blood caused by medications such as biotherapeutics (Aster and Bougie 
2007). An acute severe, self-limiting thrombocytopaenia has been found with the treatment 
of infliximab (TNF┙-specific), efalizumab [CD11a-specific; (Tamhane and Gurm 2008)] and 
rituximab (CD20-specific), but the mechanisms of action remain unknown. 
G. Dermatitis 
The EGFR-specific antibodies such cetuximab and panitumumab can commonly cause a 
skin rash on the face and upper torso (Perez-Soler and Saltz 2005). The dermatitis is thought 
to be part of the pharmacodynamic action of these agents, because EGFR is widely 
expressed on epithelial cells (Bianchini et al. 2008). 
H. Cardiotoxicity 
Trastuzumab, a humanized monoclonal antibody targeting HER2, has  been  used to treat 
HER2-positive metastatic breast cancer (Hudis 2007). However in the trials, cardiotoxicity as 
an unexpected adverse event was discovered (Force and Kerkela 2008). This cardiac 
dysfunction caused by trastuzumab is target-related, because blocking HER2 signaling 
causes mitochondrial outer membrane permeabilization and eventually apoptosis of cardiac 
muscle cells with impaired contractility and ventricular function (Kuramochi et al. 2006).  
I. Cytokine storm 
Cytokine storm is an uncontrolled hypercytokinaemia that causes multiple organ damage. It 
is a prominent side effect with CD3 specific [muromonab; (Plevy et al. 2007)], CD52 specific 
[alemtuzumab; (Wing et al. 1996; Wing et al. 1995)] and CD20 specific [rituximab; (Winkler 
et al. 1999)]. A fully humanized monoclonal antibody TGN1412 triggered an immediate and 
severe cytokine storm when given to six healthy male volunteers (Suntharalingam et al. 
2006). 
7. Pharmacoeconomics and strategies to provide affordable biotherapeutics 
drugs 
Biotherapeutics are distinctive from traditional small molecule pharmaceuticals in terms of 
administration mode, relatively high prices, and significant disease modification. The high 
development cost and high financial risk are associated with the complex process of 
biotherapeutics drug discovery and development as seen in the previous sections. However 
the new and effective biotherapeutics drugs present society a fundamental question about 
how to make these promising drugs more affordable. One example is  Orphan drugs  whose 
prices are often substantially higher than those of other drugs, and might occur at the 
expense of  common diseases if more orphan drugs are approved (Tambuyzer 2010). In UK, 
due to the high treatment cost relative to patient benefit, National Institute of Clinical 
Excellence did not approve reimbursement for several cancer drugs including monoclonal 
antibody Avastin (Raftery 2009). In US, some health plans require more than 30% co-
insurance and some biotherapeutics can cost as high as $100,000, the financial burden on 
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patients is significant. A concern has been raised for society how to pay for these innovative 
drugs (Zhong 2010).  
Pharmacoeconomic evaluation and value-based analysis, which serve to guide optimal 
healthcare resource allocation, have been used for new drug reimbursement and coverage 
(Cohen and Wilson 2009; Neumann 2009). But the direct application of these evaluation in 
health policy recommendation and formulation remains highly debated (Neumann and 
Weinstein 2010). It has been argued that weeding out inefficiencies may be more effective in 
controlling cost than denying reimbursement. From research and development standpoints, 
decreasing costs and increasing success rate for the drug approval is a critical part of 
achieving this mission. 
Clinical testing in human for new biotherapeutics drugs entails a large sum of financial 
investment. Though biotherapeutics have higher probabilities of clinical success, they have a 
higher attrition rate in phase III trials than small-molecule drugs (Grabowski 2008), 
indicating that the failure results are known only after high development cost have been 
incurred. Improving trial designs with biomarker identification and proper patient selection 
is the key to decreasing trial attrition rate. One good example is the EGFR-targeted therapy 
of colorectal cancer. Even though EGFR is widely overexpressed in tumor cells from most of 
patients, only those with a wild type KRAS phenotype will benefit from EGFR-specific 
cetuximab or panitumumab treatment (Walther et al. 2009). 
Besides increasing productivity, lowering production and processing cost is another 
important factor to provide affordable biotherapeutics treatments. Recent breakthroughs in 
production yields of mammalian cells, shortening production time, and improving 
purification and formulation for antibody production, are critical features for cost reduction. 
In addition, non-mammalian production systems such as engineered yeast and plant cells 
are being used for biotherapeutics production, which could be a substantial saving for the 
removal of costly viral inactivation validations step. 
Increasing expenditures and the high prices of biotherapeutics have highlighted the need of 
lower-cost generic substitutes for off-patent biotherapeutics drugs, usually called 
biosimilars (Ledford 2010).  
Biosimilars terminology stems from the inherent variability in the production of complex 
proteins in a living organism. As such, the innovator, or reference product has a range of 
critical quality attributes that affect the overall properties of the molecule. These attributes 
range from the fundamental amino acid sequence, through complex glycosylation. Given 
the complexity of these molecules, the determination of biosimilarity is a broad assessment 
of similarity, encompassing advanced analytical techniques, and nonclinical and clinical 
assessments. It is the confluence of these data that allow for the assessment of biosmilarity. 
Typically, the biosimilar process begins with the reverse engineering of the reference 
innovator product. While the amino acid sequence may be published, variability must be 
confirmed. Additionally, post-translational modification, such as glycosylation profile must 
be determined analytically as these are dependent upon the cell line, fermentation 
conditions and purification process. The glycoforms on the protein often contribute not only 
to their pharmacokinetics, but their inherent activity. Once the critical quality attributes are 
determined, cell line development is used to determine an appropriate cell line and subclone 
to produce a molecule within the desired attribute framework. While molecule dependent, it 
is likely that some nonclinical and clinical work will be necessary to demonstrate 
biosimilarity. Clinical experience may be required to ensure the safety and efficacy of the 
biosimilar. The level of clinical experience may range from human bioequivalence up 
www.intechopen.com
 
Drug Discovery and Development – Present and Future 
 
374 
through and including non-inferiority/equivalence studies based upon efficacy. 
Additionally, the post market surveillance of biosimilars will be important in understanding 
their long term safety profile relative to the innovator molecule.  
The regulatory requirements for biosimilar approval should be sufficiently high to ensure 
that patient safety and efficacy are assured so that these important treatments can be used 
with confidence.  
At this point in time, at least 12 biosimilar products, encompassing human growth hormone, 
erythropoietin, and granulocyte colony-stimulating factors, have been authorized for 
marketing. Some complex biotherapeutics such as antibody of rituximab are approved 
locally in India, China, and South Korea. The US Food and Drug Administration has been 
developing guidelines that will expand the development of biosimilars since it received the 
authority to approve biosimilars as part of President Barack Obama’s health-care reforms. 
The introduction of biosimilars will make a number of biotherapeutics drugs significantly 
affordable when their patents expire. The EMEA has published biosimilar guidelines, as 
have other countries. Additionally, the World Health Organization (WHO) has developed a 
position paper on the development of biosimilars.  
8. Conclusions and perspectives 
Tremendous progress has been made in the research and development of biotherapeutics 
drugs. Much has been learnt from the scientific and clinical experiences of these biological 
molecules. New technologies and new discoveries are always emerging, yet many 
challenges remain. Identifying and validating new targets, addressing oral delivery of 
biotherapeutics drugs, and improving phase III success rate, are a few to be named. The 
advent of age of biosimilars will surely make biotherapeutics drugs more accessible and 
economical. The key is striking a balance between the incentives for cost saving and 
rewarding innovation. 
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